Giving Children with Cancer the Right Treatment at the Right Time

Douglas S. Hawkins, MD

Seattle Children's Hospital, University of Washington

CHILDREN'S ONCOLOGY GROUP


Coalition Against Childhood Cancer Annual Summit

June 23, 2022

Topics for today

- Role of clinical trials to define standards of care
 - Power of randomized studies
 - How information is shared
 - FDA approval of pediatric indications
- Increased importance of molecular testing
- Access to investigational agents
- Increasing equity in treatment outcome

Childhood Cancer Facts




- Cancer is the leading cause of death from disease in children
- Progress requires multi-institutional collaboration given rarity of pediatric cancer

CA Cancer J Clin 2022;72:7-33


Children's Oncology Group (COG)

- Formed in 2000 by merger of four legacy pediatric oncology cooperative groups
- NCI-funded National Clinical Trial Network (NCTN) member; four other US adult cooperative groups
- Fast facts:
 - > 220 institutions in US (~200), Canada, Australia, New Zealand
 - > 8000 members
 - ~80-90% of children with cancer in US are treated at COG institutions






Active COG Studies: 2015-2021



COG Average Risk Medulloblastoma Trial

- 2004-2014
- 549 enrolled patients
- Two randomizations:
 - Whole PF vs involved field RT
 - 3-7 years: 18 vs 23.4 Gy CS RT
- Impact of CS RT intervention differed by molecular subgroup





CHILDREN'S ONCOLOGY GROUP


Michalski JM, J Clin Oncol 2021; 39:2685-2697

COG High Risk Medulloblastoma/PNET Trial

- 2007-2018
- 294 enrolled patients
- Two randomizations:
 - +/- isotrentinoin
 - +/- carboplatin during RT
- Improved outcome with carboplatin during RT in Group 3 only







С

CHILDREN'S ONCOLOGY GROUP

Leary SES, JAMA Oncology 2021; 7:1313-1321



AHOD1331

Activated: 03/16/2015 Closed: 08/02/2019 Version Date: 06/22/2020 Amendment #: 6

CHILDREN'S ONCOLOGY GROUP

AHOD1331

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults Phase 3 study of advanced Hodgkin lymphoma

- Randomized +/- brentuximab
- Activated: March 2015
- Last enrollment: April 2019
- Data & Safety Monitoring Committee released results: 1/18/22

Castellino S, ASCO 2022

Data & Safety Monitoring Committee

- Independent committee with experts in statistics, clinical trials, and patient advocacy
- Reviews unblinded side effect and outcome data
- Follows prospective rules defined in the protocol
- Has authority to stop studies early and release data when statistical goals are met or safety boundary is crossed

CHILDREN'S ONCOLOGY GROUP



AHOD1331

Activated: 03/16/2015 Closed: 08/02/2019


GROUP

Version Date: 06/22/2020 Amendment #: 6

CHILDREN'S ONCOLOGY GROUP

AHOD1331

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults



 Phase 3 study of advanced Hodgkin lymphoma

- Randomized +/- brentuximab
- Activated: March 2015
- Last enrollment: April 2019
- Data & Safety Monitoring Committee released results: 1/18/22
- COG website posting: 1/31/22
- Manuscript submitted: 5/19/22
- Presentation at ASCO: 6/3/22

Castellino S, ASCO 2022

What COG does and does not do

• COG does:


- Conduct large clinical trials, especially randomized studies
- Include small, medium, and large institutions
- Facilitate the collection of biospecimens for research

• COG does not:

- Determine standard of care
- Provide medical care
- Provide second-opinion consultation



COG Institutional Enrollment on Phase 3/Pilot Studies 2019-2021



What COG does and does not do

• COG does:


- Conduct large clinical trials, especially randomized studies
- Include small, medium, and large institutions
- Facilitate the collection of biospecimens for research

COG does not:

- Determine standard of care
- Provide medical care
- Provide second-opinion consultation




Cooperative Group Clinical Trial Enrollment



*Age 0-19 years only; compared to estimated number of cases based upon SEER data

CHILDREN'S Oncology Group	JNCI 1996; 88: 812-816; Cancer 2009; 115:3808-3816; PLOS ONE 2020; 15:e0230824

COG Enrollment vs Expected by Histology



*Age 0-9 years only; compared to estimated number of cases based upon SEER data, 2004-2015

CHILDREN'S ONCOLOGY GROUP PLOS ONE 2	020; 15:e0230824
--	------------------

How COG facilitates care outside of studies

- Publish study results quickly (we try)
- COG studies used by institutions to set standards of care
- Completed study protocols on COG website
- COG members are on National Comprehensive Cancer Network (NCCN) committees for treatment standards:
 - Pediatric Hodgkin lymphoma
 - Pediatric mature B cell lymphoma
 - Pediatric ALL
 - Wilms tumor

We all talk with each other

CHILDREN'S ONCOLOGY GROUP

Topics for today

- Role of clinical trials to define standards of care
 - Power of randomized studies
 - How information is shared
 - FDA approval of pediatric indications
- Increased importance of molecular testing
- Access to investigational agents
- Increasing equity in treatment outcome

CHILDREN'S ONCOLOGY GROUP


Cancer drug development is slow in children

- In 1997-2017, 117 nonhormonal chemotherapy agents approved by FDA
- Only 6 (5.1%) included children in the initial approval

CHILDREN'S

ONCOLOGY GROUP

 Median delay between firstin-human and first-in-child studies: 6.5 years



Neel DV, Eur J Cancer 2019; 112:49-56

COG studies used for pediatric labeling by FDA


Pediatric labeling	Agent	Indication	COG study
2005	Nelarabine	T-cell leukemia/lymphoma	P9673
2006	PEG asparaginase	Acute lymphoblastic leukemia	1962
<u>2011</u>	Erwinia asparaginase	Acute lymphoblastic leukemia	AALL07P2
2011 2013	Imatinib	Ph+ chronic myelogenous leukemia Ph+ acute lymphoblastic leukemia	AAML0123 AALL0031
2015	Dinutuximab	Neuroblastoma	ANBL0032
<u>2017</u>	<u>Pembrolizumab</u>	Hodgkin lymphoma, MSI-H, TMB-H	<u>ADVL1621</u>
<u>2018</u>	SC-PEG asparaginase	Acute lymphoblastic leukemia	AALL07P4
<u>2018</u>	<u>Blinatumomab</u>	Acute lymphoblastic leukemia	<u>AALL1121</u>
<u>2019</u>	<u>Dasatinib</u>	Ph+ acute lymphoblastic leukemia	<u>AALL1122</u>
2020	Gemtuzumab Ozogamicin	Acute myelogenous leukemia	AAML0531
<u>2021</u>	<u>Crizotinib</u>	Anaplastic large cell lymphoma	ADVL0912
<u>2021</u>	Liposomal daunorubicin/cytarabine	Acute myelogenous leukemia	AAML1421
<u>2021</u>	Recombinant Erwinia asparaginase	Acute lymphoblastic leukemia	<u>AALL1931</u>
<u>2021</u>	<u>Rituximab</u>	CD20+ non-Hodgkin lymphoma	ANHL1131

Topics for today

- Role of clinical trials to define standards of care
 - Power of randomized studies
 - How information is shared
 - FDA approval of pediatric indications
- Increased importance of molecular testing
- Access to investigational agents
- Increasing equity in treatment outcome



Larotrectinib for NTRK-fused solid tumors



CHILDREN'S ONCOLOGY GROUP

Drison A, N Engl J Med 2018; 378:731-739

	Institution	N	Tumor Types	Potentially Actionable Findings	Matched Targeted Therapy	Germline Findings	Reference
PEDS- MIONCOSEQ	U Michigan	102	High Risk (HR) Solid, CNS, Heme	46%	14 (33%)	10%	Mody et al. JAMA, 2015
BASIC3	Baylor	150	New Diagnosis Solid, CNS	39%	ND	10%	Parsons et al, JAMA Onc, 2016
iCat	Dana Farber CUIMC, UCSF DC Childrens	101	HR Solid	34%	3 (10%)	ND	Harris et al. JAMA Onc, 2016
INFORM	German Ca (20 centers)	57	HR Solid, CNS Heme	50%	10 (38%)	4%	Worst et al. Eur J Cancer, 2016
ClinOmics	POB/ NCI	59	HR Solid	41%	2 (8%)	12%	Chang et al. Clin Cancer Res. 2016
PIPseq	Columbia/ CHONY	101	HR Solid, CNS, Heme	38%	6 (16%)	14%	Oberg et al. Genome Med, 2016
MBB	Institut Curie	60	HR Solid, CNS	40%	6 (26%)	ND	Pincez et al. PBC, 2017

Courtesy of Julia Glade Bender, MD


Genomic sequencing for patient care

- Historically, genomic testing limited to institutions with internal support or grant funding
- Insurance coverage for genomic testing inconsistent
- Turn-around time for genomic testing may be too long to impact treatment

Identifying a potential target does not provide access to investigational agent


CHILDREN'S Oncology Group

NCI-COG Pediatric MATCH Study






NCI-COG Pediatric MATCH Study



CHILDREN'S ONCOLOGY GROUP

Parsons DW, J Clin Oncol, in press


NCI-COG Pediatric MATCH



CHILDREN'S Oncology Group


Parsons DW, J Clin Oncol, in press

NCI-COG Pediatric MATCH: Race, Ethnicity



GROUP

NCI-COG Pediatric MATCH Study



CHILDREN'S ONCOLOGY GROUP

Parsons DW, J Clin Oncol, in press

Pediatric MATCH Successes/Failures


Successes:

- > 1300 patients enrolled at 138 US COG institutions
- Central molecular testing completed in 95% of cases
- Paired diagnostic specimens
- aMOI for 31% of patients; 13% enrolled on treatment

• Failures:

- Limited responses:
 - Selumetinib (0/20), Tazemetostat (1/20), Ulixertinib (0/20)
- All arms are single agent

CHILDREN'S ONCOLOGY GROUP Parsons DW, J Clin Oncol, in press; Eckstein OS, J Clin Oncol, in press Chi SN, ASCO 2022; Vo KT, ASCO 2022



**Safety run-in ☆ First Wave

Pediatric MATCH Stage 2

- Pediatric MATCH re-opened to enrollment March 7, 2022
- Centralized molecular testing replaced by commercial or academic testing
- Reduced number of arms, no new arms
- Open to Canadian, Australian, and New Zealand sites



NCI-COG Pediatric MATCH Study

Protocol ID	Agent Class	Agent	Status
APEC1621-A	TRK Inhibitor	Larotrectinib	Open
APEC 1621-B	FGFR Inhibitor	Erdafitinib	Temporarily suspended
APEC 1621-C	EZH2 Inhibitor	Tazemetostat	Completed
APEC 1621-D	PI3K/mTOR Inhibitor	LY3023414	Open
APEC 1621-E	MEK Inhibitor	Selumetinib	Completed
APEC 1621-F	ALK Inhibitor	Ensartinib	Open
APEC 1621-G	BRAF Inhibitor	Vemurafenib	Closed for low accrual
APEC 1621-H	PARP Inhibitor	Olaparib	Closed for low accrual
APEC 1621-I	CDK 4/6 inhibitor	Palbociclib	Temporarily suspended
APEC 1621-J	MAPK pathway inhibitor	Ulixertinib	Completed
APEC 1621-K	IDH1 inhibitor	Ivosidenib	Open
APEC 1621-M	H-RAS inhibitor	Tipifarnib	Open
APEC 1621-N	RET inhibitor	Selpercatinib	Open

Genomic sequencing for patient care

- Historically, genomic testing limited to institutions with internal support or grant funding
- Insurance coverage for genomic testing inconsistent
- Turn-around time for genomic testing may be too long to impact treatment


What about genomic sequencing at initial diagnosis?



Molecular Characterization Initiative

- Patients enter by enrolling on APEC14B1 registry/biobanking study, Project:EveryChild
- Will roll out in stages:
 - CNS tumors started March 21, 2022
 - Soft Tissue Sarcomas
 - Rare Tumors
- Estimating 3000 patients annually

CHILDREN'S ONCOLOGY GROUP



Molecular Characterization Initiative

- Enhanced whole exome sequencing (WES), tumor and blood
- RNA Archer Fusion-Plex assay, tumor
- Illumina 850K Epic DNA methylation array, tumor and blood



Molecular Characterization Initiative

- Open to children with selected diagnoses through COG Project:EveryChild
- Comprehensive molecular testing at diagnosis, including germline
- Return of results to patients and treating physicians with 21 days of receipt of material

CHILDREN'S Oncology Group

Results may refine diagnosis and suggest alternative treatments

	Institution	N	Tumor Types	Potentially Actionable Findings	Matched Targeted Therapy	Germline Findings	Reference
PEDS- MIONCOSEQ	U Michigan	102	High Risk (HR) Solid, CNS, Heme	46%	14 (33%)	10%	Mody et al. JAMA, 2015
BASIC3	Baylor	150	New Diagnosis Solid, CNS	39%	ND	10%	Parsons et al, JAMA Onc, 2016
iCat	Dana Farber CUIMC, UCSF DC Childrens	101	HR Solid	34%	3 (10%)	ND	Harris et al. JAMA Onc, 2016
INFORM	German Ca (20 centers)	57	HR Solid, CNS Heme	50%	10 (38%)	4%	Worst et al. Eur J Cancer, 2016
ClinOmics	POB/ NCI	59	HR Solid	41%	2 (8%)	12%	Chang et al. Clin Cancer Res. 2016
PIPseq	Columbia/ CHONY	101	HR Solid, CNS, Heme	38%	6 (16%)	14%	Oberg et al. Genome Med, 2016
MBB	Institut Curie	60	HR Solid, CNS	40%	6 (26%)	ND	Pincez et al. PBC, 2017


Courtesy of Julia Glade Bender, MD

COG germline study of rhabdomyosarcoma

- 627 children with rhabdomyosarcoma
- Clinical annotation available
- 7.8% pathogenic/ likely pathogenic variant
- Additional genes identified


CHILDREN'S

ONCOLOGY GROUP



Li H, J Natl Cancer Inst 2021; 113:875-883

COG germline study of rhabdomyosarcoma



CHILDREN'S ONCOLOGY GROUP

Martin-Giacalone B, manuscript under preparation

Topics for today

- Role of clinical trials to define standards of care
 - Power of randomized studies
 - How information is shared
 - FDA approval of pediatric indications
- Increased importance of molecular testing
- Access to investigational agents
- Increasing equity in treatment outcome

COG Developmental Therapeutics

- Organizational structure driven by terms of NCI grant
- Overlying principles:
 - Limited network of institutions
 - Phase 1 vs phase 2 sites
- Linkage to disease committee strategies



COG PEP-CTN

- Core member sites
 limited to 21 institutions
- In 2021, added 21 additional non-core members sites
- Phase 1 restricted to core-member sites


CHILDREN'S ONCOLOGY GROUP



PEP-CTN Core Member Institutions

COG PEP-CTN





Core Member InstitutionsNon-Core Member Institutions



Investigational trial options

- Industry-sponsored
 - Limited number of institutions participating
 - Designed to meet regulatory requirements
- Single institution studies
- Multi-institutional consortia:
 - SJCRH: medulloblastoma, ALL, AML, Hodgkin lymphoma
 - DFCI: ALL

Multiple non-COG consortia



PACIFIC PEDIATRIC **NEURO-ONCOLOGY** CONSORTIUM

connect










PBTC



TACL Therapeutic Advances in Childhood Leukemia & Lymphoma




Relapsed patients struggle to find therapies



Child with relapsed AML

THE UNIVERSITY OF CHICAGO	PEDIATRIC CANCER	June 7, 2022	€ @PedsDataCommons
	DATA COMMONS	INTERNAL/CONFIDENTIAL	commons.uchicago.edu

Relapsed patients struggle to find therapies



CHICAGO

PEDIATRIC CANCER DATA COMMONS

June 7, 2022 INTERNAL/CONFIDENTIAL J @PedsDataCommons commons.uchicago.edu

ClinicalTrials.gov is difficult to use

Inclusion Criteria

- Patient must be enrolled on APAL2020SC (NCT04726241)
- Patients must be < 18 years of age at the time of study enrollment
- Patients, with or without Down syndrome (DS), and with de novo acute myeloid leukemia, therapy-related acute myeloid leukemia, myeloidysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane according to APAL2020SC screening results and meet one of the following:
- Second or greater relapse or refractory AML as defined below, including isolated extramedullary disease (EMD), but excluding isolated central nervous system (CNS) or isolated testicular disease
- Second or greater relapse or refractory myelodysplastic syndrome (MDS)
- Second or greater relapse or refractory mixed phenotype acute leukemia (MPAL)
- · Bone marrow relapse: (patients must meet one of the following criteria to be defined as having relapse disease)
- A single bone marrow sample showing >= 5% leukemic blasts by flow cytometry performed at the central laboratory, fluorescence in situ hybridization (FISH) testing or other molecular method
- A single bone marrow with at least two tests showing >= 1% leukemic blasts; examples of tests include:
- Flow cytometry showing leukemia >= 1% by multidimensional flow cytometry (MDF) performed at the central laboratory (performed at hematologics through the screening study APAL2020SC)
- · Karyotypic abnormality with at least one metaphase similar or identical to diagnosis
- · FISH abnormality identical to one present at diagnosis
- Polymerase chain reaction (PCR) or next generation sequencing (NGS)-based demonstration of leukemogenic lesion identical to diagnosis and >= 1%
- In cases where a bone marrow aspirate cannot be obtained because of extensive fibrosis, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy. A complete blood count documenting the presence of at least 1,000/ uL (i.e., a white blood count [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) can also be used if a bone marrow aspirate or biopsy cannot be performed
- · Extramedullary relapse: Biopsy proven extramedullary disease after documented complete remission
- Refractory disease: Following a re-induction cycle after a second relapse, presence of ≥1% leukernic blasts by flow cytometry performed at the central laboratory (performed only
 at Hematologics through the screening study APAL2020SC), OR there is persistent extramedullary disease
- Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
- Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age. Patients must have a performance status corresponding to Eastern Cooperative
 Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, eg, blood count criteria, the patient is considered to have recovered adequately
- · Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive
- >= 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea
- NOTE: Cytoreduction with hydroxyurea must be discontinued >= 24 hours prior to the start of protocol therapy
- Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid


 Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (eg. pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur Partial inclusion criteria for PEPN2113

"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane"

CHICAGO

June 7, 2022 INTERNAL/CONFIDENTIAL y [™] PedsDataCommons commons.uchicago.edu

Relapsed patients struggle to find therapies



CHICAGO

PEDIATRIC CANCER DATA COMMONS

June 7, 2022 INTERNAL/CONFIDENTIAL € TedsDataCommons commons.uchicago.edu

PATIENT INFORMATION	OPEN TRIALS	
Demographics	A Matched (0)	^
What is the patient's current age (in years)?	Undetermined (9)	^
What is the patient's current weight (in kg)?	APAL2020SC	· ~
Disease	V AAML2112	· ·
Prior treatment	→ APAL2020B	(i) ~
Organ function Biomarkers	> PEPN2113	<u>ن</u> ~
RESET	APAL2020D	· ~
	AAML2020E	· ·
	APAL2020F	· ·
	APAL2020G	· ·
	T2017-002	· ·
	Unmatched (0)	^

Clinical trials Information about enrollment Study locations

Patient characteristics Disease characteristics Lab tests Genomic testing

THE UNIVERSITY OF
CHICAGOPEDIATRIC CANCER
DATA COMMONSJune 7, 2022Data CommonsJune 7, 2022June 7, 2022Data CommonsINTERNAL/CONFIDENTIALCommons.uchicago.edu

THE UNIVERSITY OF CHICAGO

PEDIATRIC CANCER DATA COMMONS

June 7, 2022 INTERNAL/CONFIDENTIAL

Ƴ@PedsDataCommons commons.uchicago.edu

יד 🛦	nis site is a prototype	created for demo purposes only.	
			Hello, demo
PATIENT INFORMATION		OPEN TRIALS	
Demographics	^	Matched (3)	^
What is the patient's current age (in years)?		APAL2020SC	(i) v
What is the patient's current weight (in kg)?		APAL2020D	(i) ~
Does most recent blast percentage measuremen 1 log increase from a measurement 7 days prior?		APAL2020G	<u>ن</u> ~
○ Yes ○ No Disease	Not sure	Undetermined (1)	^
What is the patient's current disease?		APAL2020B	(i) v
Acute myeloid leukemia (AML)	~		U
How many occurrences of refractory disease, inc current, has the patient experienced?	luding the	Unmatched (5)	^
0		AAML2112	· ·
How many confirmed or suspected relapses, incl current, has the patient experienced?	uding the		
1		PEPN2113	(i) v
Is the patient currently in relapse (or suspected r • Yes	elapse)? () Not sure	AAML2020E	· ·
What is the most recent measurement of the pat percentage of BM blasts?	ient's	APAL2020F	· ·
Most recent blast percentage measured by how methods (e.g. Flow, FISH, etc.)?	many	T2017-002	(j) ~
1			
Has the patient experienced Grade 4 Sinusoidal Syndrome (SOS)?	Obstructive		
	O Not sure		
🔾 Yes 🔹 O No	~		

C gearbox-frontend-pro	ototype.netlify.app		아 ☆ 🇯
	A This site is a prototype	created for demo purposes only.	
	Ox USER GUIDE		Hello, demo
PATIENT INFORMATION		OPEN TRIALS	
Demographics	^	Matched (3)	
14/h - + 1- +h +1 +1	(
What is the patient's current age	e (in years)?	APAL2020SC	(i) 🔼
10		Description	
What is the patient's current we	ight (in kg)?	This study aims to use clinical and bio	logical
40		characteristics of acute leukemias to	
Does most recent blast percenta	ge measurement represent a	eligibility for available pediatric leuke	
1 log increase from a measureme		Testing bone marrow and blood from leukemia that has come back after tre	
⊖ Yes ⊖ No	O Not sure	difficult to treat may provide informa	
		patient's leukemia that is important v	
Disease	^	to best treat it, and may help doctors	
What is the patient's current dise	ease?	diagnose and treat leukemia in childro young adults.	en, adolescents, and
Acute myeloid leukemia (AML)	~	Locations	
How many occurrences of refrac current, has the patient experien		Oncology Patient Enrollment Ne	twork (OPENI)
0	iceu:	LLS Clinical Trial Support Center	
•		ClinicalTrials.gov	
How many confirmed or suspect			
current, has the patient experien	nced?		0
1		APAL2020D	(i) v
Is the patient currently in relapse	e (or suspected relapse)?		
• Yes O No	O Not sure	APAL2020G	() v
What is the most recent measure	ement of the patient's		_
percentage of BM blasts?		Undetermined (1)	
25			
			(i) v
Most recent blast percentage me methods (e.g. Flow, FISH, etc.)?	easured by now many	APAL2020B	0 ~
1			
		Unmatched (5)	
Has the patient experienced Gra	de 4 Sinusoidal Obstructive		
Syndrome (SOS)? () Yes ONO	○ Not sure	AAML2112	(j) v
Does the patient have isolated E			0
○ Yes ○ No	O Not sure	PEPN2113	0 ~
Does the patient have adequate	BM function?		

🔺 ть	is site is intended for nilot use	only at this time and matching r	esults should not be used for eligibility assessm	pent of actual patients
	is site is intended for phot use	only at this time and matching r	esuits should not be used for eligiblity assessing	
ABOUT GEARBOX				
			OPEN TRIALS	
PATIENT INFOR	RMATION			
			Matched (2)	^
Demographics		^		• 🗖
\A/bat is the pat	ient's current age (in year	c)2	APAL2020SC	()
-	lent s current age (in year	5):	Title	
13			A Study to Test Bone Marrow an Leukemia That Has Come Back A	
			Difficult to Treat	
	ient's biological sex?	o - -	Description	
O Male		O Female	This study aims to use clinical an	
\M/bat is the pat	ient's current weight (in k	a)2	characteristics of acute leukemia eligibility for available pediatric l	
-	lent s current weight (in k	g/:	Testing bone marrow and blood	
40			leukemia that has come back afte	
Di			difficult to treat may provide info patient's leukemia that is import	
Disease		<u>^</u>	to best treat it, and may help doo	
W/bat is the pat	ient's current diagnosis?		diagnose and treat leukemia in cl young adults.	hildren, adolescents, and
		~	Link	
Acute myeloid	leukemia (AML)	~	ClinicalTrials.gov [™]	
Doos the natio	nt currently have, or have	they in the past had		
refractory dise		ancy in the past hau,	Pediatric Clinical Trial Nurse Navigat	
• Yes	⊖ No	○ Not sure	To connect with a Pediatric Clinical T Leukemia & Lymphoma Society who	
-	-	-	patient throughout the entire clinical to fill out a Clinical Trial Support Cent	
Is the patient's	disease currently refracto	ory?	our pediatric oncology nurses will cal	ll your patient within 1
O Yes	○ No	○ Not sure	business day and provide you with a trial search results.	copy of the individualized

THE UNIVERSITY OF CHICAGO

PEDIATRIC CANCER DATA COMMONS June 7, 2022 INTERNAL/CONFIDENTIAL Ƴ@PedsDataCommons commons.uchicago.edu

FDA's Expanded Access Program (EAP)

- Path to obtain investigational agent outside of trial
- 99% single patient use (SPU) requests approved
- High proportion of pediatric requests (34% overall)
- Four large institutions, 2014-2019:
 - Genomically targeted agents only
 - 45 SPUs for 44 patients
 - Most common reason: no clinical trial available (64.4%)
 - Median time for FDA approval: 3 days
 - Objective response rate: 39.5%

CHILDREN'S ONCOLOGY GROUP Feit NZ, JAMA Oncol 2019; 5:570-572 Sabnis HS, J Clin Oncol 2021; 39:3822-3828

Topics for today

- Role of clinical trials to define standards of care
 - Power of randomized studies
 - How information is shared
 - FDA approval of pediatric indications
- Increased importance of molecular testing
- Access to investigational agents
- Increasing equity in treatment outcome

CHILDREN'S ONCOLOGY GROUP




GROUP

JNCI J Natl Cancer Inst (2021) 113(3): djaa107

doi: 10.1093/jnci/djaa107 First published online November 24, 2020 Article

Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma

Kira Bona (), MD, MPH,^{1,*} Yimei Li (), PhD,² Lena E. Winestone (), MD,³ Kelly D. Getz (), MPH,^{2,4} Yuan-Shung Huang (), MS,⁵ Brian T. Fisher, DO, MPH, MSCE,^{4,6} Ami V. Desai, MD, MSCE,⁷ Troy Richardson (), PhD,⁸ Matt Hall, PhD,⁸ Arlene Naranjo, PhD,⁹ Tara O. Henderson, MD, MPH,⁷ Richard Aplenc (), MD, PhD, MSCE,^{4,10,11} Rochelle Bagatell, MD¹¹




- Enrolled on COG high-risk neuroblastoma immunotherapy studies
- Everyone had initial protocol treatment and anti-GD2 antibody
- Disparity of outcome by household poverty

Bona K, J Natl Cancer Inst 2021; 113:282-291

Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study

Justine M. Kahn, MD, MS¹; Kara M. Kelly, MD²; Qinglin Pei, PhD³; Rizvan Bush, MS⁴; Debra L. Friedman, MD, MS⁵; Frank G. Keller, MD⁶; Smita Bhatia, MD, MPH⁷; Tara O. Henderson, MD, MPH⁸; Cindy L. Schwartz, MD⁹; and Sharon M. Castellino, MD, MSc⁶




- Enrolled on COG Hodgkin lymphoma studies
- No difference in EFS by race or ethnicity
- Disparity of post-relapse survival by race, ethnicity

CHILDREN'S Oncology Group

Kahn JM, J Clin Oncol 2019; 37:3009-3017

Pediatric cancer survival by neighborhood

- 4417 children with cancer 1.00diagnosed 1992-2013 in Washington 0.75-
- Census data to define:
 - Rural residence
 - Neighborhood poverty (ADI)
- Lower survival for either rural residence or high ADI




CHILDREN'S ONCOLOGY GROUP

Ohlsen TJD, ASCO 2022

Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

Smita Bhatia, Wendy Landier, Muyun Shangguan, Lindsey Hageman, Alexandra N. Schaible, Andrea R. Carter, Cara L. Hanby, Wendy Leisenring, Yutaka Yasui, Nancy M. Kornegay, Leo Mascarenhas, A. Kim Ritchey, Jacqueline N. Casillas, David S. Dickens, Jane Meza, William L. Carroll, Mary V. Relling, and F. Lennie Wong

- Oral chemotherapy is major part of treatment for ALL
- Does it matter if children take it?





Bhatia S, J Clin Oncol 2012; 30:2094-2101

Conclusions

- Clinical trials are essential to define standard treatment, improve outcome, and support FDA pediatric labeling
- Molecular testing is often needed to guide therapy
- Many paths to access investigational agents; none are easy
- Reducing the inequities of access, opportunity, and delivery are central to improve pediatric cancer outcomes

CHILDREN'S ONCOLOGY GROUP

Thanks to CAC2 for the invitation and your advocacy



COG Annual Supporters

CHILDREN'S ONCOLOGY GROUP

